Prophylactic Effect of a Therapeutic Vaccine against TB Based on Fragments of Mycobacterium tuberculosis

Vilaplana, Cristina; Gil, Olga; Cáceres, Neus; Pinto, Sérgio Wyton Lima; Díaz, J.F.; Cardona, Père-Joan

doi:10.1371/journal.pone.0020404

Cited by 47 publications

(19 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was developed to complete latent TB treatment after a short course of antimicrobial therapy [85,86]. Experimental data showed that RUTI® is safe and able to elicit T H 1-T H 2-T H 3 responses in animal models.…”

Section: Resultsmentioning

confidence: 99%

Vaccine against tuberculosis: what’s new?

et al. 2014

View full text Add to dashboard Cite

Backgroundone of the World Health Organization Millennium Development Goal is to reduce tuberculosis incidence by 2015. However, more of 8.5 million tuberculosis cases have been reported in 2011, with an increase of multidrug-resistant strains. Therefore, the World Health Organization target cannot be reach without the help of a vaccine able to limit the spread of tuberculosis. Nowadays, bacille Calmette-Guérin is the only vaccine available against tuberculosis. It prevents against meningeal and disseminated tuberculosis in children, but its effectiveness against pulmonary form in adolescents and adults is argued.Methoda systematic review was performed by searches of Pubmed, references of the relevant articles and Aeras and ClinicalTrial.gov websites.Results100 articles were included in this review. Three viral vectored booster vaccines, five protein adjuvant booster vaccines, two priming vaccines and two therapeutic vaccines have been analyzed.ConclusionsSeveral vaccines are in the pipeline, but further studies on basic research, clinical trial and mass vaccination campaigns are needed to achieve the TB eradication target by 2050.

show abstract

Section: Resultsmentioning

confidence: 99%

Vaccine against tuberculosis: what’s new?

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The various TB protein vaccines in human clinical trials include fusion proteins of Ag85B/ESAT‐6 in adjuvant IC31 (Van Dissel et al., ), Ag85B/ESAT‐6/Rv2660c in adjuvant IC31 (Lin et al., ), Ag85B/ESAT‐6 in CAF01 (Kamath et al., ), Ag85B/TB10.4 in IC31 adjuvant (Skeiky et al., ), Rv1196/Rv0125 in adjuvant AS01 or AS02 (Von Eschen et al., ) and Rv2608/Rv3619/Rv3620/Rv1813 in glucopyranosyl lipid adjuvant (Bertholet et al., ). The two therapeutic vaccines that are designed to shorten or enhance chemotherapy are the RUTI vaccine based on detoxified liposomal cellular fractions of M. tuberculosis (Vilaplana et al., ) and killed M. vaccae (Dlugovitzky et al., ).…”

Section: Tuberculosis Vaccines In Human Clinical Trialsmentioning

confidence: 99%

Overview of Vaccination Trials for Control of Tuberculosis in Cattle, Wildlife and Humans

Buddle

Parlane

Wedlock

et al. 2013

Transbound Emerg Dis

View full text Add to dashboard Cite

SummaryVaccination is a key strategy for control of tuberculosis (TB), and considerable progress has been made in the past 5 years to develop improved vaccines for humans and animals, differentiate vaccinated animals from those infected with Mycobacterium bovis and deliver vaccines to wildlife. Studies have moved from testing vaccines in small animal models to clinical trials in humans and from experimental challenge studies in cattle and wildlife to evaluation of vaccines in the field. Candidate vaccines undergoing testing in humans include live mycobacterial vaccines to replace bacille Calmette Gu erin (BCG), subunit vaccines (virus vector or protein) to boost BCG and therapeutic vaccines used as an adjunct to chemotherapy. In cattle, a number of diagnostic tests have been developed and successfully tested for differentiating infected from vaccinated animals, which will facilitate the use of BCG vaccine in cattle. Encouraging results have been obtained from recent field trials in cattle using BCG vaccine to protect against natural exposure to M. bovis. To date, no subunit TB vaccines have induced improved protection compared with that for BCG, but prime-boost combinations of BCG with DNA, protein or virus-vectored vaccines have induced better protection than BCG vaccine alone. Development of an oral bait BCG formulation has demonstrated the practicality of delivering TB vaccines to wildlife. Oral BCG preparations have induced protection against experimental challenge of M. bovis in possums, badgers, wild boar and white-tailed deer and against natural exposure to M. bovis in possums. Recent progress in TB vaccine development has provided much impetus for their future use.

show abstract

“…20,21 However, considerable variability was observed with M. vaccae, 22,23 and RUTI was able to reduce bacilli loads (around 0.5 log) in the lung, but not in the spleen of guinea pigs. 24 As mentioned before, these limitations are due to the inherent On the other hand, the CD4 + IL-17 + cells were reported to represent as few as 1% of the CD4 + T cells in the lungs of M. tuberculosis infected mice, 32 while we observed around 5% at 60 d and more than 15% at 120 d post-infection.…”

Section: Discussionmentioning

confidence: 59%